Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2013:2013:852839.
doi: 10.1155/2013/852839. Epub 2013 Aug 25.

New hypothesis on pathogenesis of ovarian cancer lead to future tailored approaches

P Rescigno  1 , I Cerillo, R Ruocco, C Condello, S De Placido, M Pensabene
Affiliations
Review

New hypothesis on pathogenesis of ovarian cancer lead to future tailored approaches

P Rescigno et al. Biomed Res Int. 2013.

Abstract

In the last decades, management of epithelial ovarian cancer (EOC) has been based on the staging system of the International Federation of Gynecology and Obstetrics (FIGO), and different classifications have been proposed for EOC that take account of grade of differentiation, histological subtype, and clinical features. However, despite taxonomic efforts, EOC appears to be not a unique disease; its subtypes differ for epidemiological and genetic risk factors, precursor lesions, patterns of spread, response to chemotherapy, and prognosis. Nevertheless, carboplatin plus paclitaxel combination represents the only standard treatment in adjuvant and advanced settings. This paper summarizes theories about the classification and origin of EOC and classical and new prognostic factors. It presents data about standard treatment and novel agents. We speculate about the possibility to create tailored therapy based on specific mutations in ovarian cancer and to personalize prevention.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Pathogenesis of different EOCs according to Prat.
See this image and copyright information in PMC

References

    1. GLOBOCAN 2008 v1.2. Cancer Incidence and Mortality Worldwide. Lyon, France: IARC Press; 2010. (IARC CancerBase, no. 10). http://globocan.iarc.fr/
    1. Heintz AP, Odicino F, Maisonneuve P, et al. Carcinoma of the ovary. FIGO 26th annual report on the results of treatment in gynecological cancer. International Journal of Gynaecology and Obstetrics. 2006;95(supplement 1):S161–S192. - PubMed
    1. Colombo N, Guthrie D, Chiari S, et al. International Collaborative Ovarian Neoplasm trial 1: a randomized trial of adjuvant chemotherapy in women with early-stage ovarian cancer. Journal of the National Cancer Institute. 2003;95(2):125–132. - PubMed
    1. Piccart MJ, Bertelsen K, James K, et al. Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results. Journal of the National Cancer Institute. 2000;92(9):699–708. - PubMed
    1. Burger RA, Brady MF, Bookman MA, et al. Incorporation of bevacizumab in the primary treatment of ovarian cancer. The New England Journal of Medicine. 2011;365:2473–2483. - PubMed

Substances

LinkOut - more resources